LEADER

Anti-tumour necrosis factor

Anti-tumour necrosis factor therapy: can we afford it?

D P M Symmons

Correspondence to:
Correspondence to:
Professor D P M Symmons
ARC Epidemiology Unit, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK; deborah.symmons@man.ac.uk

---

Cost is now a factor in selecting treatment

---

Keywords: rheumatoid arthritis; modelling; cost effectiveness; cost utility analysis; tumour necrosis factor ; adalimumab

The first 150 words of the full text of this article appear below.

The introduction of biological agents into the therapeutic armamentarium for rheumatoid arthritis (RA) has ushered in a new era for rheumatologists in more ways than one. Randomised controlled trials (RCTs) and longitudinal observational studies provide clear evidence that the use of these agents is associated with a greater proportion of responders and a better response than with conventional disease modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX).^1–9 However, these drugs are substantially more expensive than conventional DMARDs. This means that, whether we like it or not (and most of us don’t like it), cost is now one of the factors we have to consider when selecting treatment for patients with RA. Perhaps for the first time rheumatologists are having to take part in the process of healthcare policy making and endeavour to understand the language of cost effectiveness analysis (CEA). CEA compares the incremental cost of an . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Humbert, M. (2007). Dual endothelin receptor antagonism: setting standards in PAH. ERR 16: 13-18 [Abstract] [Full Text]  
• Capell, H. A, Madhok, R., Porter, D. R, Munro, R. A L, McInnes, I. B, Hunter, J. A, Steven, M., Zoma, A., Morrison, E., Sambrook, M., Wui Poon, F., Hampson, R., McDonald, F., Tierney, A., Henderson, N., Ford, I. (2007). Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 66: 235-241 [Abstract] [Full Text]  
• Bansback, N. J., Ara, R., Barkham, N., Brennan, A., Fraser, A. D., Conway, P., Reynolds, A., Emery, P. (2006). Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) 45: 1029-1038 [Abstract] [Full Text]